Stocks · News reference
Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst maintains Buy rating and $2.50 PT.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-16 AccNo: 0001493152-26-047404 Size: 208 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 9.01: Financial Statements and Exhibits
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $9.25 to $9.5.
BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.